Our R&D Pipeline
Our specially -formulated 900mg dose of N-acetylcysteine, has been studied in extensively in various clinical entities which have been called Cysteine/Glutathione Deficiency.
Starting many years ago with known actions in decreasing the thickness of lung mucus, even when consumed orally, we have also backed research to understand how correcting CGD’might strengthen the functional immune response or increase lung function.
Cysteine/Glutathione Deficiency, being a corollary of disease, may have a broad clinical manifestation, including cytokine-cascade induced inflammation (influenza), chronic viral infection (HIV-1 disease), acquired lung dysfunctions (COPD), or genetic disease states (cystic fibrosis).
Apart from glutathione influences, n-acetylcysteine is being studied for its effects on glutamate as a neurotransmitter. Research is underway to develop solutions for patients with glutamate signaling problems associated with symptoms of Autism Spectrum Disorder, PTSD, and other conditions that share common neurobiology.
Alcoholism, sex addiction, shopping addiction, tricotilomania, explosive anger syndrome, bipolar disorder, and other psychiatric conditions cause significant economic and social cost to patients and their families. For example, researchers are studying whether altering target metabolic functions can decrease cravings, outbursts, and impulsivity, and allow people to manage their lives better.
Misuse of acetaminophen-containing products is the leading cause of acute liver failure. Most acetaminophen overdose incidents are accidental. We want to pull together the resources to develop a safer standard of clinical care in relieving pain and lowering fever.